289 related articles for article (PubMed ID: 21030558)
1. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Fang HB; Cai L; Janofsky S; Chew A; Storek J; Akpek G; Badros A; Yanovich S; Tan MT; Veloso E; Pasetti MF; Cross A; Philip S; Murphy H; Bhagat R; Zheng Z; Milliron T; Cotte J; Cannon A; Levine BL; Vonderheide RH; June CH
Blood; 2011 Jan; 117(3):788-97. PubMed ID: 21030558
[TBL] [Abstract][Full Text] [Related]
2. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
3. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.
Rapoport AP; Stadtmauer EA; Aqui N; Vogl D; Chew A; Fang HB; Janofsky S; Yager K; Veloso E; Zheng Z; Milliron T; Westphal S; Cotte J; Huynh H; Cannon A; Yanovich S; Akpek G; Tan M; Virts K; Ruehle K; Harris C; Philip S; Vonderheide RH; Levine BL; June CH
Clin Cancer Res; 2009 Jul; 15(13):4499-507. PubMed ID: 19509133
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
[TBL] [Abstract][Full Text] [Related]
5. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.
Stadtmauer EA; Vogl DT; Luning Prak E; Boyer J; Aqui NA; Rapoport AP; McDonald KR; Hou X; Murphy H; Bhagat R; Mangan PA; Chew A; Veloso EA; Levine BL; Vonderheide RH; Jawad AF; June CH; Sullivan KE
Blood; 2011 Jan; 117(1):63-71. PubMed ID: 20864577
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW
Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
9. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.
Rapoport AP; Stadtmauer EA; Aqui N; Badros A; Cotte J; Chrisley L; Veloso E; Zheng Z; Westphal S; Mair R; Chi N; Ratterree B; Pochran MF; Natt S; Hinkle J; Sickles C; Sohal A; Ruehle K; Lynch C; Zhang L; Porter DL; Luger S; Guo C; Fang HB; Blackwelder W; Hankey K; Mann D; Edelman R; Frasch C; Levine BL; Cross A; June CH
Nat Med; 2005 Nov; 11(11):1230-7. PubMed ID: 16227990
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
Rosenblatt J; Avivi I; Vasir B; Uhl L; Munshi NC; Katz T; Dey BR; Somaiya P; Mills H; Campigotto F; Weller E; Joyce R; Levine JD; Tzachanis D; Richardson P; Laubach J; Raje N; Boussiotis V; Yuan YE; Bisharat L; Held V; Rowe J; Anderson K; Kufe D; Avigan D
Clin Cancer Res; 2013 Jul; 19(13):3640-8. PubMed ID: 23685836
[TBL] [Abstract][Full Text] [Related]
11. Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma.
Cohen AD; Lendvai N; Nataraj S; Imai N; Jungbluth AA; Tsakos I; Rahman A; Mei AH; Singh H; Zarychta K; Kim-Schulze S; Park A; Venhaus R; Alpaugh K; Gnjatic S; Cho HJ
Cancer Immunol Res; 2019 Apr; 7(4):658-669. PubMed ID: 30745365
[TBL] [Abstract][Full Text] [Related]
12. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
13. Current developments in immunotherapy in the treatment of multiple myeloma.
Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
[TBL] [Abstract][Full Text] [Related]
14. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial.
Berntsen A; Trepiakas R; Wenandy L; Geertsen PF; thor Straten P; Andersen MH; Pedersen AE; Claesson MH; Lorentzen T; Johansen JS; Svane IM
J Immunother; 2008 Oct; 31(8):771-80. PubMed ID: 18779742
[TBL] [Abstract][Full Text] [Related]
16. Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies.
Ocadlikova D; Kryukov F; Mollova K; Kovarova L; Buresdova I; Matejkova E; Penka M; Buchler T; Hajek R; Michalek J
Neoplasma; 2010; 57(5):455-64. PubMed ID: 20568900
[TBL] [Abstract][Full Text] [Related]
17. Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.
Freeman CL; Atkins R; Varadarajan I; Menges M; Edelman J; Baz R; Brayer J; Castaneda Puglianini O; Ochoa-Bayona JL; Nishihori T; Shain KH; Shah B; Chen DT; Kelley L; Coppola D; Alsina M; Antonia S; Anasetti C; Locke FL
Clin Cancer Res; 2023 Nov; 29(22):4575-4585. PubMed ID: 37735756
[TBL] [Abstract][Full Text] [Related]
18. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
Minnie SA; Hill GR
Front Immunol; 2021; 12():651288. PubMed ID: 33777050
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.
Condomines M; Veyrune JL; Larroque M; Quittet P; Latry P; Lugagne C; Hertogh C; Kanouni T; Rossi JF; Klein B
J Immunol; 2010 Jan; 184(2):1079-84. PubMed ID: 19966210
[TBL] [Abstract][Full Text] [Related]
20. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
